Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study

Qifeng Wang1,2,3,4†, Fen Li5†, Qingming Jiang6†, Yifeng Sun7†, Qiong Liao4,8, Huimin An4,9, Yunzhu Li8, Zhenyu Li6, Lifang Fan10, Fang Guo10, Qinghua Xu4,7,11,12, Yixin Wo7, Wanli Ren7, Junqiu Yue4,10*, Bin Meng4,13*, Weiping Liu14* and Xiaoyan Zhou1,2,3,4*

1 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China, 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, 3 Institute of Pathology, Fudan University, Shanghai, China, 4 The Cancer of Unknown Primary Group of Pathology Committee, Chinese Research Hospital Association, Shanghai, China, 5 Department of Pathology, Chengdu Second People’s Hospital, Chengdu, China, 6 Department of Pathology, Chongqing University Cancer Hospital, Chongqing, China, 7 The Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd., Hangzhou, China, 8 Department of Pathology, Sichuan Cancer Hospital, Chengdu, China, 9 Department of Pathology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China, 10 Department of Pathology, Huabei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 11 The Institute of Machine Learning and Systems Biology, College of Electronics and Information Engineering, Tongji University, Shanghai, China, 12 Xuzhou Engineering Research Center of Medical Genetics and Transformation, Department of Genetics, Xuzhou Medical University, Xuzhou, China, 13 Department of Pathology, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, 14 Department of Pathology, West China Hospital, Sichuan University, Chengdu, China

Background: Liver metastases (LM) are the most common tumors encountered in the liver and continue to be a significant cause of morbidity and mortality. Identification of the primary tumor of any LM is crucial for the implementation of effective and tailored treatment approaches, which still represents a difficult problem in clinical practice.

Methods: The resection or biopsy specimens and associated clinicopathologic data were archived from seven independent centers between January 2017 and December 2020. The primary tumor sites of liver tumors were verified through evaluation of available medical records, pathological and imaging information. The performance of a 90-gene expression assay for the determination of the site of tumor origin was assessed.

Result: A total of 130 LM covering 15 tumor types and 16 primary liver tumor specimens that met all quality control criteria were analyzed by the 90-gene expression assay. Among 130 LM cases, tumors were most frequently located in the colorectum, ovary and breast. Overall, the analysis of the 90-gene signature showed 93.1% and 100% agreement rates with the reference diagnosis in LM and primary liver tumor, respectively. For the common primary tumor types, the concordance rate was 100%, 95.7%, 100%, 93.8%, 87.5% for classifying the LM from the ovary, colorectum, breast, neuroendocrine, and pancreas, respectively.
INTRODUCTION

Liver metastases (LM) are tumors that have propagated to the liver from tumors originating from other parts of the body. Due to the venous blood returning from the gastrointestinal system through portal vein circulation, gastrointestinal tract tumors are more likely to metastasize to the liver (1). Besides, the liver microenvironment also plays a significant role in the development of hepatic metastasis. Numerous studies have shown that both the acellular such as extracellular matrix proteins (i.e. collagen) and the cellular components of the liver such as Kupffer cells, hepatic stellate cells and liver sinusoidal endothelial cells contribute to the metastatic ability of tumors of different origins (2). According to the statistical data in the Surveillance, Epidemiology and End Results (SEER) database, 5.14% to 6.46% of cancer patients are diagnosed with synchronous LM at the time of primary cancer diagnosis (3, 4). Of note, during the course of the cancer disease, up to 50% of patients with various tumor types will either present with or develop LM (1). The most common tumor that spreads to the liver is breast cancer for younger women and colorectal cancers for younger men (3). In the current era, several studies investigated that the incidence rate of cancer of unknown primary (CUP) is currently decreasing and reaches 1-2% (5). Liver CUP is the most common CUP subgroup (30–40%) and has the most dismal prognosis with median overall survival (OS) of 1–2 months and one-year OS of 5–12% (6).

The prognosis of LM varies to tumor types. LM originated from small intestine cancer shows the best prognosis, followed by testis cancer and breast cancer (4). Traditionally, the treatment approaches were established according to the primary tumor of LM. For example, resection can be usually performed in patients with colorectal liver metastases (CLM) and neuroendocrine tumor liver metastases (NETLM), but it may not be appropriate for patients with LM from pancreatic cancer, esophageal cancer, melanoma and adrenocortical cancer (1). In addition, different tumor types carry specific genetic alterations, genomic feature analysis which could provide precise and pertinent clinical details for disease management. For CLM patients, information on the mutation status of oncogenes such as BRAF, NRAS, and KRAS as well as analysis of microsatellite instability (MSI) status have led to precise therapy and prognostic stratification (7). Therefore, identification of the primary tumor of any LM is pivotal for the implementation of valid and tailored treatment options, which still acts as a troublesome problem in the clinical setting. In most cases, metastatic tumors with representative histological features similar to the primary lesion can be correctly distinguished with hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC) (8). However, the distinction between intrahepatic cholangiocarcinoma and metastatic adenocarcinoma is frequently challenging owing to the overlapping phenotypic profiles (9).

Over the last decades, molecular profiling has been under speed development for predicting tumor site of origins in CUP patients (10, 11). According to the tumor origin, specific gene expression profiling has been well recognized in most tumor types, which reflects the different expression profilings in their normal tissues of origin. Differences in gene expression pattern thus allow distinction between various solid tumors and provide a valuable method for diagnosis of the tissue of origin in CUP patients. Recently, our group has developed a 90-gene expression assay for the classification of 21 common tumor types which represent approximately 95% of the incident solid tumors that are known to produce distant metastases. In a retrospective cohort of 609 clinical specimens, the 90-gene expression assay illustrated an overall accuracy of 90.4% for primary tumors and 89.2% for metastatic tumors. Furthermore, in a real-world cohort of 141 CUP patients, the gene expression assay was able to provide instructive predictions of primary tumors in 71.6% of patients (101 of 141). These findings suggest that the 90-gene expression assay could efficiently identify the primary site for a broad spectrum of tumor types and support its diagnostic utility of molecular classification in difficult-to-diagnose metastatic tumors (12). Recently, Wang et al. performed the 90-gene expression assay for the differential diagnosis of metastatic triple-negative breast cancer (TNBC) (13). This assay correctly identified 97.6% of TNBC lymph node metastases (41 of 42) and 96.8% of distant metastatic tumors (30 of 31). Zheng et al. investigated the potential utility of the 90-gene expression assay in diagnosing the tumor origin of brain tumors (14). The molecular assay illustrated 100% accuracy for discriminating primary brain tumors from brain metastases and accurately predicted primary sites for 89% of brain metastases (39 of 44).

In the present study, we conducted a multi-center retrospective study based on seven cancer centers in China to assess the performance of the 90-gene expression assay and explore its potential diagnostic utility for LM.

MATERIAL AND METHODS

Patient Enrollment and Specimen Acquisition

The study protocol was approved by the institutional review board of Fudan University Shanghai Cancer Center (FUSCC, Shanghai, China), West China Hospital Sichuan University (WCHSU, Chengdu,
were provided in samples with the Ct values of reference genes greater than 38 target genes were normalized to multiple reference genes. For was initiated at 95°C for 10 minutes, followed by 40 cycles at 95°C

7500 Real-Time PCR system (Applied Biosystems) to analyze was initiated at 95°C for 10 minutes, followed by 40 cycles at 95°C

Foster City, CA), the 90-gene real-time PCR (RT-PCR) assay

Gene Expression Pro

Sample Preparation and RNA Isolation

Five to five fifteen 5μm unstained sections were freshly cut for gene expression analysis. The FFPE tissue samples were centralized and the H&E-stained slide of each case had been reviewed for evaluation of the percentage of tumor cells and necrotic areas by two senior pathologists from FUSCC (QF W and XY Z). The regions of tumor tissue were marked on the H&E-stained slides and macro-dissected manually for tumor cells enrichment. Total RNA isolation and gene expression profiling were performed at the Canhelp Genomic Reference Laboratory (Hangzhou, China). Total RNA was extracted using a FFPE Total RNA Isolation Kit (Canhelp Genomics, Hangzhou, China) according to the protocols. Briefly, FFPE tissue was deparaffinized, followed by digestion, DNase treatment and total RNA elution. The concentration of total RNA was measured by spectrophotometer at 260-nm absorbance, and the purity was quantified using A260/A280 ratio. RNA samples with A260/A280 ratios between 1.7 and 2.1 were enrolled in this study.

90-Gene Classifier for Tumor Classification: Algorithm Development and Data Analysis

Initially, the cancer-specific gene markers were identified based on a pan-cancer transcriptome database comprising 5434 specimens representing 21 tumor types (15). The database included both primary and metastatic tumors and well-differentiated to undifferentiated tumors. The SVM-RFE (Support Vector Machine-Recursive Feature Elimination) machine learning algorithm was used to select the Top-10 most predictive genes for each of the 21 tumor types. After removing redundant genes, a list of 90 genes specific to 21 tumor types was identified. Details of the 90-gene list were provided in Supplementary Table 3. Then, an SVM linear model was trained using the whole pan-cancer transcriptome database to form a multiclass classification algorithm ("90-gene classifier").

Mathematically, the 90-gene classifier creates a hyperplane for each tumor type in a 90-dimensional space. For an unknown test sample, the algorithm calculates its 90 genes’ expression values, projects it to the 90-dimensional space, and estimates the distance of the test sample to each of 21 hyperplanes. The position of the test sample relative to the hyperplane determines its membership in one or the other class (e.g., “breast cancer” vs. “not breast cancer”). Furthermore, the confidence of the test sample belongs to a tumor type is proportional to the distance of the test sample from the corresponding hyperplane. The far the distance, the higher the confidence. Then, the distances of the test sample from each of the 21 hyperplanes were compared and transformed to the similarity scores with the Platt Scaling formula (16). Intuitively, the similarity scores reflect how much the gene expression pattern of the test sample is similar to the global gene expression pattern of the indicated tumor type. The similarity scores were probability-based, with a reported range from 0 to 100, and all 21 scores sum to 100. The tumor type with the highest similarity score was defined as the predicted tumor type by the 90-gene classifier. An example was shown in Supplementary Figure 1. The primary site with the highest similarity score is gastroesophagus, thus indicating the most likely tissue of origin is gastroesophagus.

Statistical Analysis

All statistical analysis was performed using the R software (version 3.6.1) and packages from the Bioconductor project (version 3.9). The hierarchical clustering of clinical specimens based on the gene expression pattern was performed using “pheatmap” package (version 1.0.12). The average linkage hierarchical clustering method was performed where the metric of similarity was Pearson’s correlation between every pair of samples. The receiver operating characteristic (ROC) curves were estimated using “multiROC” package (version 1.1.1). The gene expression assay performance was assessed by calculating the area under curve (AUC) for each tumor type and aggregation across all tumor types. For multi-class evaluation, the AUC for all tumor types was calculated through a micro-averaging approach, which stacked all tumor
types together, thus converting the multiclass classification into binary classification. The micro-averaging approach further considered the contributions of different tumor types and weight metrics toward the largest type when some tumor types have more instances than others. P-value was computed two-sided and considered as statistically significant if p-value < 0.05.

RESULTS

Patients and Samples
Initially, 156 FFPE specimens covering 16 primary tumor types were collected in the present study, 148 had successful histologic quality control and 146 of these samples passed the RT-PCR quality control. More specifically, seven specimens were excluded because of less than 60% tumor cell content, one because of more than 40% necrosis, and two because of RT-PCR quality control failures. Finally, 130 LM and 16 primary liver tumor specimens met all quality control criteria and were successfully analyzed by the 90-gene expression assay. The overall study design is presented in Figure 1. The sample enrollment of seven center hospitals was shown in Supplementary Table 4.

The demographics and clinical characteristics of the cohort are provided in Table 1. The cohort included 63 males and 83 females, with a median age of 57.5 years old (range 14-83). All specimens were taken from the liver, of which 36 were biopsy samples and 110 were resection samples. The origin of LM came from 15 primary sites and the most common tissue of origin were colorectum (n=23) and ovary (n=23), followed by breast (n=19), neuroendocrine (n=16), pancreas (n=16) and gastroesophagus (n=10). Other relatively rare tumor types comprising melanoma (n=4), cervix (n=4), lung (n=3), adrenal (n=3), germ cell (n=2), head&neck (n=2), sarcoma (n=2), kidney (n=2) and urinary (n=1) were also included. Among 146 samples, the degree of differentiation of 97 cases was defined, 26 (26.8%) cases were well-differentiated, whereas 71 (73.2%) cases were poorly differentiated.

Performance of the 90-Gene Expression Assay in Liver Tumors
For primary liver tumors, the 90-gene expression assay correctly classified all 16 samples showing a 100% accuracy. For 130 LM
cases, the 90-gene expression assay achieved a 93.1% (121/130, 95% CI: 0.87-0.97) accuracy by comparing the predicted tumor types with the reference diagnosis. The AUC of the Top-5 common tumor types ranged from 0.945 to 1 (Figures 2A–E), and the weighted AUC for all tumor types reached 0.981 (Figure 2F). As shown in Table 2, the sensitivities of the 90-gene expression assay are variable, ranging from 50% (head&neck) to 100% (ovary, breast, melanoma, etc.).

Of the 146 specimens, 26 were well or moderately differentiated tumors, 71 were poorly or undifferentiated tumors, and 49 were not specified. More specifically, the classification accuracy was 96.2% (25 of 26) for well or moderately differentiated tumors and 88.7% (63 of 71) for poorly or undifferentiated tumors, with no statistically notable difference (p = 0.47). In addition, the present study enrolled 36 biopsy specimens and 110 resection specimens. The overall accuracy of 90-gene expression assay showed no significant difference between biopsy and resection groups, (88.9% and 95.4%, respectively, p value equals 0.31).

In subgroup analysis, the neuroendocrine tumors were specified (n=4), gastrointestinal (n=1), esophagus (n=1), thyroid (n=2), ovary (n=1), esophagus (n=1), lung (n=1) and undefined (n=4), with an overall accuracy of 93.8% (15/16). For ten cases of squamous cell carcinoma, their origins were composed of the cervix (n=4), gastroesophageal (n=3), head&neck (n=2), and lung (n=1). The 90-gene signature correctly classified the tissue of origin in 7 of 10 cases (70%).

To illustrate the similarity between clinical samples, we performed hierarchical clustering based on primary liver cancer and six main metastatic tumor types (n >5). As shown in Figure 3, the samples were clustered into distinct groups that followed the tumor types based on the 90-gene expression pattern. The primary liver tumor samples were clustered together and showed distinct patterns from six LM types. Among LM types, digestive system neoplasms including colorectal, gastroesophageal, and pancreatic tumors were more likely to share similar gene expression patterns. For example, most of gastroesophageal tumors were clustered together, whereas few samples were similar to colorectal, pancreatic tumors.

A total of nine LM cases had discordant predictions compared with reference diagnoses. The histological types of nine misclassified samples included gastroesophageal (n=3), pancreas (n=2), lung (n=1), colorectum (n=1), neuroendocrine (n=1) and head&neck (n=1). Among nine cases, five were adenocarcinoma, three were squamous cell carcinoma and one was a neuroendocrine tumor. Eight of nine cases were poorly differentiated. The detailed characteristics of the discordant cases were investigated in Table 3.

**DISCUSSION**

LM is the most common tumors encountered in the liver and continues to be a notable factor for morbidity and mortality. The identification of the primary tumor in the conditions of any LM is critical to define optimal management. In clinics, imaging modalities such as ultrasonography, CT, Magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are typically most often applied for LM diagnosis (17). Hui et al. developed B-mode ultrasound radiomic models to distinguish the origin of liver metastatic lesions from the digestive tract tumor, lung tumor and breast tumor, with the sensitivity ranging from 70% to 75% (18). Moreover, serum tumor markers can potentially aid in the diagnosis of patients with LM. For instance, carcinoembryonic antigen (CEA) is one of the most crucial tumor markers for colorectal cancer. Other useful biomarkers for LM diagnosis include CA 19-9 (pancreaticobiliary cancer), chromogranin A (neuroendocrine tumor), CA 15-3 (breast cancer) and CA-125 (germinal tumor) (19). Although these serum markers are indicative for certain primary tumors, their specificities are still limited (19). For instance, the increase of serum CEA level may indicate the presence of colorectal cancer, but it can be also observed in 30-60% of pancreatic cancer patients (20).

Histological examinations including morphological and IHC analyses are the gold standard for tumor origin diagnosis. However, most of the LM originated from adenocarcinoma, which shares overlapping histological features with primary liver tumors or between each other (1). Thus, additional

**TABLE 1 | The demographics and clinical characteristics of the cohort.**

| Characteristic          | Number of specimens (N = 146) | Percentage (%) |
|-------------------------|-------------------------------|----------------|
| **Gender**              |                               |                |
| Male                    | 63                            | 43.2           |
| Female                  | 83                            | 56.8           |
| **Age**                 |                               |                |
| Median                  | 57.5                          |                |
| Range                   | 14-83                         |                |
| **Tumor types**         |                               |                |
| Liver                   | 16                            | 11.0           |
| Colorectum              | 23                            | 15.8           |
| Ovary                   | 23                            | 15.8           |
| Breast                  | 19                            | 13.0           |
| Neuroendocrine          | 16                            | 11.0           |
| Pancreas                | 16                            | 11.0           |
| Gastroesophagus         | 10                            | 6.8            |
| Melanoma                | 4                             | 2.7            |
| Cervix                  | 4                             | 2.7            |
| Lung                    | 3                             | 2.1            |
| Adrenal                 | 3                             | 2.1            |
| Germ cell               | 2                             | 1.4            |
| Head&neck               | 2                             | 1.4            |
| Sarcoma                 | 2                             | 1.4            |
| Kidney                  | 2                             | 1.4            |
| Urinary                 | 1                             | 0.7            |
| **Histological Subtype**|                               |                |
| Adenocarcinoma          | 114                           | 78.1           |
| Neuroendocrine          | 16                            | 11.0           |
| Squamous cell           | 10                            | 6.8            |
| carcinoma               |                               |                |
| Melanoma                | 4                             | 2.7            |
| Sarcoma                 | 2                             | 1.4            |
| **Degree of differentiation** |                         |                |
| Well-differentiated     | 26                            | 26.8           |
| Poorly differentiated    | 71                            | 73.2           |

*The degree of differentiation of 48 specimens was undefined.*
organ-specific IHC panels are crucial to characterize the tumor origin. A combination cytokeratin (CK) panel CK7/CK20 is recommended for initial evaluation (1, 8, 21). For example, CK7(-)/CK20(+) tumors may originate from colorectum, CK7(+)/CK20(+) tumors may originate from pancreas, biliary tract and gastroesophageal, etc., CK7(+)/CK20(-) tumors may originate from breast and ovary, etc., and CK7(-)/CK20(-) tumors may originate from hepatocellular carcinoma and squamous cell carcinoma (8, 21). However, many tumors express more than one phenotype, especially in gastrointestinal carcinoma. In a recent meta-analysis, IHC analysis correctly distinguished the primary site in 77.7% of metastatic liver cancers with the average usage of 6.9 ± 4.1 markers (8).

In recent years, several gene expression profiling-based assays were developed to identify the primary site of metastatic tumors. This technique is based on the theory that tumors share distinct gene expression patterns specific to their sites of origin (22). A commercial assay called CancerTYPE ID (Biotheranostics, San Diego, CA, USA), which is a RT-PCR assay involves 92 genes, allowing the identification of 28 common tumor types (23). A multisite validation study done by Sarah et al. demonstrates an overall sensitivity of 87% in primary site identification (24).

Another assay named Tissue of Origin (TOO) test (Vyant Bio, New Jersey, USA) is microarray-based and measured the gene expression pattern of 1550 genes that related to 15 tumor types. In a multicenter cohort of 547 specimens, the TOO assay accurately classified 87.8% of cases (25). Over the past decades, DNA methylation profiling have been developed rapidly, which could be a useful approach to unmask the primary site of CUP. Sebastian et al. reported a DNA-methylation-based assay termed
“EPICUP” for predicting primary sites of CUP (26). In a clinical validation set, EPICUP predicted a primary tumor of origin in 87% of CUP patients. More interestingly, patients with EPICUP diagnoses who received a tumor type-specific therapy showed improved overall survival compared with that in patients who received empiric therapy. However, neither of these assays has been validated in a large cohort of liver biopsy samples. Recently, only Katharina et al. reported a microRNA classifier showing an overall classification accuracy of 74.5% for primary site identification of liver biopsy specimens (27). This result was unsatisfactory for solving the urgent need of LM diagnosis in the clinic.

In the present study, the 90-gene expression assay achieved a precise classification of the tumor origin in 146 liver tumors with an overall accuracy of 93.8%, which was comparable to the EPICUP with 94% (501 of 534) accuracy in metastatic tumors (26). Moreover, the performance of the 90-gene expression assay was significantly better than the accuracy of the gold standard histopathology (77.7%) (8). In practice, the turnaround time of the 90-gene expression assay from archived FFPE samples to tumor type prediction was less than one day, which might greatly shorten patients’ waiting time compared with the conventional histopathological evaluation. These results indicated that the 90-gene expression assay might serve as a useful tool for accurately identifying the tissue of origin for liver tumors. In the daily diagnostic routine, FFPE liver biopsy specimens are widely used

| Tumor type    | Number of samples | Correctly classified samples by the gene expression assay | Sensitivity (%) |
|---------------|-------------------|--------------------------------------------------------|----------------|
| Ovary         | 23                | 23                                                     | 100            |
| Colon         | 23                | 23                                                     | 100            |
| Breast        | 19                | 19                                                     | 100            |
| Neuroendocrine| 16                | 15                                                     | 93.8           |
| Pancreas      | 16                | 14                                                     | 87.5           |
| Gastroesophage| 10                | 7                                                      | 70.0           |
| Melanoma      | 4                 | 4                                                      | 100            |
| Cervix        | 4                 | 4                                                      | 100            |
| Lung          | 3                 | 2                                                      | 66.7           |
| Adrenal       | 3                 | 3                                                      | 100            |
| Germ Cell     | 2                 | 2                                                      | 100            |
| Head&Neck     | 2                 | 1                                                      | 50.0           |
| Sarcoma       | 2                 | 2                                                      | 100            |
| Kidney        | 2                 | 2                                                      | 100            |
| Urinary       | 1                 | 1                                                      | 100            |
| Total         | 130               | 121                                                    | 93.1           |

FIGURE 3 | Hierarchical clustering analysis of 90 genes in 123 specimens. The average linkage hierarchical clustering method was performed where the metric of similarity was Pearson’s correlation between every pair of samples. The left panel shows a dendrogram of hierarchical clustering of 90 genes. Colored pixels capture the magnitude of the gene expression intensities, where shades of blue and red represent under-expression and over-expression, respectively, relative to the mean for each gene. The upper panel shows a dendrogram of hierarchical clustering of samples. The clinical features such as degree of differentiation, histological types, gender and tumor types of each sample are indicated in the upper panel. The number of tumor types less than five are not shown.
First, the performance of the 90-gene expression assay is variable across different tumor types due to small enrolled number of certain tumor types. For example, the sensitivity is ranged from 50% (head&neck) to 100% (ovary, breast, melanoma, etc.). Further validation of the 90-gene expression assay on larger numbers of head&neck origin LM, gastroesophageal origin LM, rare LM types, and poorly differentiated LM are warranted. Second, although the 90-gene expression assay demonstrated an accuracy of 100% in classifying the neuroendocrine tumors from various origins, however, it was unable to evaluate the discriminating performance of the panel to distinguish the tumor origins of neuroendocrine tumors.

**CONCLUSION**

In conclusion, the results of the present study demonstrate encouraging performance of the 90-gene expression assay for distinguishing primary liver tumor from LM and identifying the primary sites of LM. In cases that morphology and IHC analyses cannot confirm the tissue of origin, the 90-gene expression assay maybe serves as a helpful instrument for discriminating the primary tumor. Future incorporation of the 90-gene expression assay in clinical diagnosis will aid oncologists in applying precise treatments, leading to improved care and outcomes for LM patients. In future studies, additional effort needs to be done for the distinguishing of head&neck origin LM, gastroesophageal origin, rare LM types, or poorly differentiated LM.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the institutional review board of Fudan University.

---

**TABLE 3 | Investigation of nine cases misclassified by the 90-gene expression assay.**

| ID  | Gender | Age | Sample type | Pathological diagnosis | Histological Subtype | Degree of differentiation |
|-----|--------|-----|-------------|------------------------|---------------------|--------------------------|
| 43  | Male   | 69  | Surgery     | Gastroesophagus        | Urinary             | AC                       | Poorly                   |
| 54  | Male   | 61  | Surgery     | Colorectum             | Gastroesophagus      | AC                       | Poorly                   |
| 57  | Male   | 70  | Biopsy      | Pancreas               | Colorectum           | AC                       | Poorly                   |
| 59  | Male   | 74  | Biopsy      | Gastroesophagus        | Liver               | AC                       | Poorly                   |
| 70  | Male   | 53  | Biopsy      | Pancreas               | Liver               | AC                       | Poorly                   |
| 75  | Male   | 63  | Biopsy      | Lung                   | Head&neck           | SCC                      | Poorly                   |
| 114 | Male   | 59  | Surgery     | Gastroesophagus        | Liver               | NET                      | Poorly                   |
| 119 | Female | 68  | Surgery     | Neuroendocrine         | Endometrium          | SCC                      | Poorly                   |
| 134 | Female | 63  | Surgery     | Head&neck             | Liver               | SCC                      | Poorly                   |

AC: Adenocarcinoma; SCC: Squamous cell carcinoma; NET: Neuroendocrine tumor.
Shanghai Cancer Center (FUSCC, Shanghai, China), West China Hospital Sichuan University (WCHSU, Chengdu, Sichuan, China), Sichuan Cancer Hospital (SCH, Chengdu, Sichuan, China), Chongqing Cancer Hospital (CCH, Chongqing, China), Tianjin Medical University Cancer Institute & Hospital (TMUCHIH, Tianjin, China), Sir Run Run Shaw Hospital (SRRSH, Hangzhou, Zhejiang, China) and Hubei Cancer Hospital (HCH, Wuhan, Hubei, China). Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

XZ, WL, BM, and JY designed the study. QW, FL, QI, QL, HA, YL, ZL, LF, FG, and BM provided the specimens and collected clinical information. YS, YW, and WR performed the experiments. QW, YS, and QX analyzed all data. QW and YS wrote the initial manuscript draft. XZ, WL, BM, and JY critically revised the manuscript and gave valuable insight to the study concept. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Tsilimigras DI, Brodt P, Clavien P-A, Muschel RJ, D'Angelica MI, Endo I, et al. Liver Metastases. *Nat Rev Dis Primers* (2021) 7(1):1–23. doi: 10.1038/s41572-021-00261-6
2. Brodt P. Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. *Clin Cancer Res* (2016) 22(24):5991–8. doi: 10.1158/1078-0432.CCR-16-0460
3. Horn SR, Stoltzfus KC, Lehrer EI, Dawson LA, Tchelebi L, Gusani NJ, et al. Epidemiology of Liver Metastases. *Cancer Epidemiol* (2020) 67:101760. doi: 10.1016/j.canep.2020.101760
4. Wang S, Feng Y, Swinnen J, Oyen R, Li Y, Ni Y. Incidence and Prognosis of Liver Metastasis at Diagnosis: A Pan-Cancer Population-Based Study. *Am J Cancer Res* (2020) 10(5):1477–517.
5. Rassy E, Pavlidis N. The Currently Declining Incidence of Cancer of Unknown Primary. *Cancer Epidemiol* (2019) 61:139–41. doi: 10.1016/1096.0606
6. Rassy E, Pavlidis N. Progress in Refining the Clinical Management of Cancer of Unknown Primary in the Molecular Era. *Nat Publ Group* (2020) 17(9):541-54. doi: 10.1038/s41571-020-0359-1
7. Tsilimigras DI, Ntaniasis-Stathopoulos I, Bagante F, Morris D, Cloyd J, Spartalis E, et al. Clinical Significance and Prognostic Relevance of KRAS, BRAF, PI3K and TP53 Genetic Mutation Analysis for Resectable and Unresectable Colorectal Liver Metastases: A Systematic Review of the Current Evidence. *Surg Oncol* (2018) 27(2):280–8. doi: 10.1016/j.suronc.2018.05.012
8. Amin K, El-Rays D, Snover D, Mettler T, Vogel RJ, Khalifa MA. Patterns of Immunohistochemistry Utilization in Metastases to the Liver. *Immunohistochem Mol Morphol* (2019) 27(6):441–7. doi: 10.1007/PAL.000000000000643
9. Swaid F, Downs D, Rosemurgy AS. A Practical Approach to Liver Metastasis From Unknown Primary Cancer: What Surgeons Need to Know. *Cancer Genet* (2016) 209(12):559–66. doi: 10.1016/j.cancergen.2016.08.004
10. Varadharachy N. New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling. *Clin Cancer Res* (2013) 19(15):4027–33. doi: 10.1158/1078-0432.CCR-12-3030
11. Greco FA, Lennington WJ. Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology. *Diag* (2013) 105(11):782–90. doi: 10.1093/dci/djt999
12. Ye Q, Wang Q, Qi P, Chen J, Sun Y, Jin S, et al. Development and Clinical Validation of a 90-Gene Expression Assay for Identifying Tumor Tissue Origin. *J Mol Diagn* (2020) 22(9):1139–50. doi: 10.1016/j.jmoldx.2020.06.005
13. Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, et al. Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. *Front Oncol* (2019) 9:354. doi: 10.3389/fonc.2019.00354
14. Zheng Y, Ding Y, Wang Q, Sun Y, Teng X, Gao Q, et al. 90-Gene Signature Assay for Tissue Origin Diagnosis of Brain Metastases. *J Transl Med* (2019) 17(1):1–9. doi: 10.1186/s12967-019-2082-1
15. Xu Q, Chen J, Ni S, Tan C, Xu M, Dong L, et al. Pan-Cancer Transcriptome Analysis Reveals a Gene Expression Signature for the Identification of Tumor Tissue Origin. *Mod Pathol* (2016) 29(6):546–56. doi: 10.1038/modpathol.2016.60
16. Platt J. Probabilistic Outputs For Support Vector Machines and Comparisons to Regularized Likelihood Methods. *JMLR* (1999) 10(3):61–74. doi: 10.1.1.41.1639
17. Sugahana DV, Bajwa MA, Andrahli Y, Bapai S, Cusack JC. Current Status of Imaging and Emerging Techniques to Evaluate Liver Metastases From Colorectal Cancer. *Ann Surg* (2014) 259(5):861. doi: 10.1097/SLA.0000000000000525
18. Qin H, Wu Y-Q, Lin P, Gao RZ, Li X, Wang XR, et al. Ultrasound Image-Based Radiomics. *J Ultrasound Med* (2021) 40(6):1229–44. doi: 10.1002/jum.15506
19. Locker GY, Hamilton S. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. *Oncol JHOC* (2006) 24(33):5313–27. doi: 10.1200/JCO.2006.08.2644
20. Meng Q, Shi S, Liang C, Liang D, Xu W, Ji S, et al. Diagnostic and Prognostic Value of Carcinoembryonic Antigen in Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Oncol Targets Ther* (2017) 10:4591–8. doi: 10.2147/OTT.S145708
21. Seljes J, Long-Mira E, Mathieu M-C, Rochaix P, Illei M. Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. *Cancers* (2018) 10(4):108. doi: 10.3390/cancers10040108
22. Su AI, Walsh JB, Sapinsoo LM, Kemi SG, Dimitrov P, Lapp H, et al. Molecular Classification of Human Carcinomas by Use of Gene Expression Signatures. *Cancer Res* (2001) 61(20):7388–93.
23. Ma X-J, Patel R, Wang X, Salanga R, Murage J, Desal R, et al. Molecular Classification of Human Cancers Using a 92-Gene Real-Time Quantitative Polymerase Chain Reaction Assay. *Arch Pathol Lab Med* (2006) 130(4):465–73. doi: 10.1043/1543-2165/2006)130[4:465-MOCOHCU]2.0.CO;2

FUNDING

This work was partially supported by research funding from Innovation Program of Shanghai Science and Technology Committee grants 20Z11900300 (XZ), Innovation Group Project of Shanghai Municipal Health Commission grants 2019CXYQ03 (XZ), Shanghai Science and Technology Development Fund grants 19MC1911000 (XZ, QW) and Shanghai Municipal Key Clinical Specialty grants shslxzdjk01301 (XZ, QW), the National Natural Science Foundation of China grants 81,401,963 (QW) and 81,972,728 (QW), Fudan University Shanghai Cancer Center grant YJYQ201603 (QW), Health commission of Hubei Province scientific research project grant WJ2019H124 (JY), Hubei science and technology program grant 2020CFB8869 (FG) and Canhelp Genomics Co., Ltd.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.725988/full#supplementary-material
Conflict of Interest: Author YS, YW, WR, and QX were employed by the company Canhelp Genomics.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Li, Jiang, Sun, Liao, Li, Fan, Guo, Xu, Wo, Ren, Yue, Meng, Liu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.